PRESS RELEASE – Novel immune checkpoint presented at SITC 2019
30 September 2019
Season’s greetings
19 December 2019

PRESS RELEASE – Novel ICI combination with aPD1 or aCTLA4

For immediate release


Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies


Lyon, France, November 7th, 2019 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, will showcase preclinical efficacy data of a novel regulator of response to anti-PD1 and anti-CTLA4 immunotherapies.

“We are thrilled to share the data on this program”, commented Jeremy Bastid, Chief Operating Officer. “The target was identified as a master regulator of anti-PD1 and anti-CTLA4 response in resistant mouse models using our in vivo genetic screening platform”. Dr Bonnefoy further commented on the preclinical antibody data : “Similarly to the KO mice, the candidate mAb was shown to turn non-responders or partial responders to PD1 or CTLA4 targeting therapies into complete responders with long term survival in several mouse models. We have compelling evidence suggesting that the mechanism of action involves the reduction of myeloid cell infiltration as well as profound alterations in the tumor draining lymph nodes.”

The data will be presented on November 9th, 2019 during the 34th SITC annual meeting held at the Gaylord National Hotel & Convention Center in National Harbor, MD, USA. The full abstract #P286 “In vivo genetic screens in PD-1 resistant mouse models identified modulator of anti-PD1 response with relevance to pembrolizumab-treated human metastatic melanoma” has now been released and is accessible online. The poster will be displayed on Saturday, November 9th, 7:00 am – 8:30 pm. Our team, Jeremy Bastid, Chief Operating Officer of OREGA Biotech and Nathalie Bonnefoy, acting Chief Scientific Officer, will be present during the poster sessions 12:35 – 2:05 pm and 7:00 – 8:30 pm to discuss the data and provide more information on the program.

Download the press release.

About OREGA Biotech
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 and anti-CTLA4 response. Anti-CD39 antibodies were licensed to Innate Pharma in 2016 and have been further partnered with AstraZeneca/MedImmune in 2018. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.

Jeremy Bastid, Chief Operating Officer
Tel.: +33 (0)4 37 49 87 20

For more information: